TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30390646

Group type: EXPERIMENTAL
Intervention: Response inhibition smoking training (INST)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Active control group (response inhibition towards household items)
Number of subjects: 150
Study: 26917682

Group type: EXPERIMENTAL
Intervention: Heel raise
Number of subjects: 124

Group type: COMPARATOR
Intervention: Prefabricated orthoses
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Footwear replacement
Number of subjects: 124

Group type: COMPARATOR
Intervention: No footwear replacement
Number of subjects: 124
Study: 24096769

Group type: EXPERIMENTAL
Intervention: Antecolic route of gastroenteric reconstruction
Number of subjects: 246

Group type: COMPARATOR
Intervention: Retrocolic route of gastroenteric reconstruction
Number of subjects: 246
Study: 22488002

Group type: EXPERIMENTAL
Intervention: Soybean oil-based parenteral nutrition (Intralipid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Olive oil-based parenteral nutrition (ClinOleic)
Number of subjects: 100
Study: 21040626

Group type: EXPERIMENTAL
Intervention: Combination of 97 mg L-theanine and 40 mg caffeine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study: 18349061

Group type: EXPERIMENTAL
Intervention: PTH(1-84) (100 mug)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Daily PTH
Number of subjects: 50
Study: 17703634

Group type: EXPERIMENTAL
Intervention: Telmisartan/Hydrochlorothiazide combination
Number of subjects: 0
Study: 14987497

Group type: EXPERIMENTAL
Intervention: Verbal instructions on hygienic standards for collecting the sample and explanatory leaflet
Number of subjects: 515

Group type: COMPARATOR
Intervention: Control group (customary guidelines)
Number of subjects: 515
Study: 10770818

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 400 microg/day (FP400)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 800 microg/day (BDP800)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 750 microg/day (FP750)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 1500 microg/day (BDP1500)
Number of subjects: 69
Study: 9075139

Group type: EXPERIMENTAL
Intervention: Icodextrin 7.5%
Number of subjects: 23
Study: 8473588

Group type: EXPERIMENTAL
Intervention: Expectancy challenge
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Traditional information
Number of subjects: 3

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 3
Study: 3084167

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUDs (20 micrograms or 30 micrograms per day)
Number of subjects: 10600

Group type: COMPARATOR
Intervention: Copper-releasing IUD (Nova T)
Number of subjects: 10600

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUDs (LNG-IUDs)
Number of subjects: 10600
Study: 31837497

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study: 31144402

Group type: EXPERIMENTAL
Intervention: Group A: previous scores were shown before completing the PVAS
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Group B: PVAS was completed then owners were shown previous scores and asked to repeat the PVAS
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Group C: PVAS was completed as reported previously
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Group D: PVAS and a 0–10 verbal scale (VS) were completed
Number of subjects: 192

Group type: COMPARATOR
Intervention: Retrospective study
Number of subjects: 192
Study: 28251932

Group type: EXPERIMENTAL
Intervention: Lactisole (500 ppm) added to the preload and OGTT solutions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control OGTT (water preload without lactisole)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Saccharin (300 ppm) preload before OGTT
Number of subjects: 10
Study: 25651363

Group type: EXPERIMENTAL
Intervention: ZS-9 3 g three times daily for 2 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ZS-9 10 g three times daily for 2 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ZS-9 10 g
Number of subjects: 90
Study: 24049442

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 0
Study: 21315223

Group type: EXPERIMENTAL
Intervention: VerifyNow P2Y12 Assay (Accumetrics)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Hyporesponsiveness to clopidogrel based on the VerifyNow Assay
Number of subjects: 222

Group type: COMPARATOR
Intervention: VerifyNow Aspirin Assay (Accumetrics), MEA ASPI test, MEA ADP test
Number of subjects: 222
Study: 19442776

Group type: EXPERIMENTAL
Intervention: NGM/EE
Number of subjects: 2810

Group type: EXPERIMENTAL
Intervention: NETA/EE
Number of subjects: 2810

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2810
Study: 16830021

Group type: EXPERIMENTAL
Intervention: Castor oil
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 15120542

Group type: EXPERIMENTAL
Intervention: Closed head injury group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurologically intact controls
Number of subjects: 0
Study: 11131448

Group type: EXPERIMENTAL
Intervention: Etidronate 400 mg/day for 14 days every 3 months for at least 1 year with supplemental calcium
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 9052046

Group type: EXPERIMENTAL
Intervention: Ultraviolet C light (UVC) system
Number of subjects: 0
Study: 8886085

Group type: EXPERIMENTAL
Intervention: Hyalectin 20 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 110
Study: 3021443

Group type: EXPERIMENTAL
Intervention: Halothane-nitrous oxide anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normotensive epidural analgesia
Number of subjects: 20
Study: 31860209

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 865

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 865
Study: 28776873

Group type: EXPERIMENTAL
Intervention: STRIP (Systematic Tool to Reduce Inappropriate Prescribing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STRIP
Number of subjects: 0
Study: 27033260

Group type: EXPERIMENTAL
Intervention: Percutaneous biopsy
Number of subjects: 393

Group type: COMPARATOR
Intervention: No biopsy
Number of subjects: 393
Study: 24651386

Group type: EXPERIMENTAL
Intervention: Facilitated reciprocal peer review visits followed by 12 months of supported quality improvement
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study: 22686948

Group type: EXPERIMENTAL
Intervention: Educational intervention (five tailored one-to-one sessions)
Number of subjects: 159
Study: 20927416

Group type: EXPERIMENTAL
Intervention: NobelGuide System (Nobel Biocare)
Number of subjects: 20
Study: 19022835

Group type: EXPERIMENTAL
Intervention: Left ventricular pacing
Number of subjects: 39

Group type: COMPARATOR
Intervention: Right ventricular pacing
Number of subjects: 39
Study: 16086949

Group type: EXPERIMENTAL
Intervention: 350‐mm² Baerveldt glaucoma implant
Number of subjects: 212

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (0.4 mg/ml for 4 minutes)
Number of subjects: 212
Study: 12183313

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11475717

Group type: EXPERIMENTAL
Intervention: Weishu capsule (WSC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Weining granule (WNG)
Number of subjects: 75
Study: 7624468

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 8 weeks
Number of subjects: 148
Study: 2708190

Group type: EXPERIMENTAL
Intervention: Dichloroacetate infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 6
Study: 24031

Group type: EXPERIMENTAL
Intervention: NaHCO3 (alkalosis)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: NH4Cl (acidosis)
Number of subjects: 5

Group type: COMPARATOR
Intervention: CaCO3 (control)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Acidosis
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alkalosis
Number of subjects: 5
Study: 31767215

Group type: EXPERIMENTAL
Intervention: internet delivered cognitive behaviour therapy (iCBT) for eight weeks, five sessions (n=150)
Number of subjects: 302

Group type: COMPARATOR
Intervention: treatment as usual (n=152)
Number of subjects: 302
Study: 31287011

Group type: EXPERIMENTAL
Intervention: Training in child/youth mental health treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Booster training on recognition and referral
Number of subjects: 0
Study: 28371882

Group type: EXPERIMENTAL
Intervention: Piezotome-corticision assisted orthodontics
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional orthodontics (self-ligation fixed orthodontic appliance without corticision)
Number of subjects: 41
Study: 25363062

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri DSM 17938 strain supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 22878868

Group type: EXPERIMENTAL
Intervention: Nicotine treatment plus conventional therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Asymptomatic patients (n=6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Disease-free subjects (n=6)
Number of subjects: 13
Study: 21804499

Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Granisetron (Group B)
Number of subjects: 100
Study: 19538741

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) group, 1 gram diluted in 100 ml normal saline
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo group, 100 ml of normal saline
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 16442406

Group type: EXPERIMENTAL
Intervention: Intravenous low-dose vitamin K
Number of subjects: 102

Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: FFP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Vitamin K
Number of subjects: 102
Study: 14872180

Group type: EXPERIMENTAL
Intervention: Cold-adapted trivalent intranasal influenza virus vaccine (CAIV)
Number of subjects: 9689

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9689
Study: 11770835

Group type: EXPERIMENTAL
Intervention: naproxen CR (1,000 mg once daily)
Number of subjects: 159

Group type: COMPARATOR
Intervention: nabumetone (1,000 mg once daily)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: naproxen CR
Number of subjects: 159

Group type: COMPARATOR
Intervention: nabumetone
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: naproxen CR and nabumetone
Number of subjects: 159
Study: 9579815

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 37
Study: 7995183

Group type: EXPERIMENTAL
Intervention: Purepa capsules, coated, pH 5.5, 60 min time release (group C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Purepa capsules (other preparations A, B, D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Max-EPA (triglyceride preparation)
Number of subjects: 50
Study: 2741263

Group type: COMPARATOR
Intervention: Laser treatment only
Number of subjects: 137

Group type: COMPARATOR
Intervention: Laser treatment plus 5-fluorouracil 5% ointment
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Laser treatment and adjuvant 5-fluorouracil 2% painting
Number of subjects: 137
Study: 31542756

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Building better caregivers manualised group-based intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 75
Study: 29923005

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27342767

Group type: EXPERIMENTAL
Intervention: Child perceptions of health related quality of life (QOL) using the Oxford Ankle Foot Questionnaire for Children (OxAFQ‐C)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Parent perceptions of health related quality of life (QOL) using the Oxford Ankle Foot Questionnaire for Children (OxAFQ‐C)
Number of subjects: 124
Study: 25132588

Group type: EXPERIMENTAL
Intervention: Dual Axis Rotational Coronary Angiography (DARCA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional Coronary Angiography (CCA)
Number of subjects: 201
Study: 22219315

Group type: EXPERIMENTAL
Intervention: 6 μg reduced-dose seasonal trivalent influenza vaccine
Number of subjects: 234

Group type: COMPARATOR
Intervention: 15 μg conventional seasonal trivalent influenza vaccine
Number of subjects: 234
Study: 21147694

Group type: EXPERIMENTAL
Intervention: docetaxel, trastuzumab, and pertuzumab
Number of subjects: 800

Group type: COMPARATOR
Intervention: docetaxel, trastuzumab, and placebo
Number of subjects: 800
Study: 17693890

Group type: EXPERIMENTAL
Intervention: Peer-delivered, modified directly observed therapy (mDOT) for 6 weeks (30 daily visits)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 350
Study: 15848478

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LapDN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open donor nephrectomy
Number of subjects: 60
Study: 12208571

Group type: EXPERIMENTAL
Intervention: Pilocarpine 5 mg three times daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9972741

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) 50 ng x kg(‐1) x min(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7570406

Group type: EXPERIMENTAL
Intervention: Asthma self-management programme (four 2.5 hour education sessions at weekly intervals)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Asthma self-management programme
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 116
Study: 2405935

Group type: EXPERIMENTAL
Intervention: Mechanically stapled anastomoses
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hand-sewn anastomoses (single layer Maxon)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (mechanically stapled and hand-sewn)
Number of subjects: 80
Study: 466952

Group type: EXPERIMENTAL
Intervention: Glucagon (2 mg intravenous)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Glucagon (2 mg intravenous) in Series A
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no glucagon) in Series A
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no glucagon) in Series B
Number of subjects: 72
Study: 6638849

Group type: EXPERIMENTAL
Intervention: Cryoprobe analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined use of cryoprobe and morphine infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular morphine on demand
Number of subjects: 0
Study: 31298923

Group type: EXPERIMENTAL
Intervention: Complex meniscal tear
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Meniscal extrusion of at least 11%, 25%, and 20%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tear lengths of at least 7.0 mm, 6.7 mm, and 6.5 mm
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cartilage injury in the medial compartment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: More than 20% meniscal tissue excised
Number of subjects: 40
Study: 29261565

Group type: EXPERIMENTAL
Intervention: Above goal oxygen exposure (cumulative 5-day above goal oxygen exposure)
Number of subjects: 2994
Study: 26789096

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (250 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (500 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (exercise without AA supplementation)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: AA supplementation (both dosages)
Number of subjects: 46
Study: 24161333

Group type: EXPERIMENTAL
Intervention: AMG 145 (PCSK9 monoclonal antibody)
Number of subjects: 282
Study: 22515646

Group type: EXPERIMENTAL
Intervention: i.v. epoprostenol at 2 ng kg(‐1) min(‐1) for 2 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: i.v. epoprostenol at 4 ng kg(‐1) min(‐1) for 2 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: i.v. epoprostenol at 6 ng kg(‐1) min(‐1) for 2 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: i.v. epoprostenol at 8 ng kg(‐1) min(‐1) for 2 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: i.v. epoprostenol
Number of subjects: 20
Study: 19996931

Group type: EXPERIMENTAL
Intervention: High-stringency CD8-depleted DLI (starting dose: 1 x 10(6) CD4 cells/kg for unrelated, 3 x 10(6) CD4 cells/kg for related)
Number of subjects: 28
Study: 17587452

Group type: EXPERIMENTAL
Intervention: Blended-learning approach (study arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical approach (study arm B)
Number of subjects: 0
Study: 16027402

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg every 8 hours for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin + placebo
Number of subjects: 0
Study: 12412994

Group type: EXPERIMENTAL
Intervention: UDCA plus suplatast tosilate (300 mg/day tid)
Number of subjects: 38

Group type: COMPARATOR
Intervention: UDCA alone (600 mg/day tid)
Number of subjects: 38
Study: 10348784

Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin (400 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg)
Number of subjects: 8
Study: 8749228

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg 3 times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1673844

Group type: EXPERIMENTAL
Intervention: d-propranolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: racemic propranolol
Number of subjects: 11
Study: 7030977

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 39

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 39
Study: 31064406

Group type: EXPERIMENTAL
Intervention: Endotracheal tube fastener
Number of subjects: 500

Group type: COMPARATOR
Intervention: Adhesive tape
Number of subjects: 500
Study: 27683282

Group type: EXPERIMENTAL
Intervention: 600,000 IU vitamin-D
Number of subjects: 60

Group type: COMPARATOR
Intervention: 300,000 IU vitamin-D
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 25526678

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 0
Study: 23669513

Group type: EXPERIMENTAL
Intervention: Early limited formula (10 mL formula by syringe after each breastfeeding, discontinued when mature milk production began)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (continued exclusive breastfeeding)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Early limited formula
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 20972878

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training (LSR) at 50% of one repetition maximum for 10 weeks, performed twice a week with five sets of ten repetitions and 30 seconds inter-set rest period
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 18984831

Group type: EXPERIMENTAL
Intervention: Very early mobilization and task-oriented physical therapy
Number of subjects: 12
Study: 17875820

Group type: EXPERIMENTAL
Intervention: Ambient air pollution exposure (measured levels of nitrogen, sulfur and carbon oxides, and particulate matter)
Number of subjects: 40
Study: 15497601

Group type: EXPERIMENTAL
Intervention: Meridian exercise
Number of subjects: 0
Study: 12620953

Group type: EXPERIMENTAL
Intervention: Diltiazem (2 micro g x kg(‐1) x min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dopamine (2.5 micro g x kg(‐1) x min(‐1))
Number of subjects: 60
Study: 10197489

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 30
Study: 7473239

Group type: EXPERIMENTAL
Intervention: Tryptophan (3 g l-1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low dose of BCAA (6 g l-1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High dose of BCAA (18 g l-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (6% sucrose)
Number of subjects: 10
Study: 2249160

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7383488

Group type: EXPERIMENTAL
Intervention: Early mother-infant contact program during the first 12 hours after cesarean section
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional procedures allowing only brief contact during the first 12 hours
Number of subjects: 40
Study: 29999208

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to the tibia bone for 100 seconds prior to PPCI and at 24 and 72 hours post-PPCI.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-laser therapy (NLT) with power source turned off.
Number of subjects: 24
Study: 26330561

Group type: EXPERIMENTAL
Intervention: Early home-based group education on renal replacement therapy (RRT) options
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Early home-based group education on RRT options
Number of subjects: 80
Study: 24571755

Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study: 22464760

Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (4 mg/d)
Number of subjects: 472

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 472